Lukas Kirchner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lukas Kirchner has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ulrike Holzgrabe
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany
5 shared publications - Tessa Marciniak
Universität Würzburg, Würzburg, Deutschland
3 shared publications - Wilma Ziebuhr
Institute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany
3 shared publications Christine Erk
Institute for Pharmacy and Food Chemistry, University of Wurzburg, 97074 Wurzburg, Germany
2 shared publications- Oliver Scherf-Clavel
Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
2 shared publications - Christine Erk
University of Würzburg
1 shared publication
Latest Publications
- Open Access
- 3 December 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (12) , 4271-4278
Structure Elucidation of the Daptomycin Products Generated upon Heterologous Expression of the Daptomycin Resistance Gene Cluster drcAB
Recently, a high-level daptomycin (DAP)-resistant Mammaliicoccus sciuri strain (TS92) was identified, which mediates a 33% decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here, we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promoter on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine and, subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.
- 3 December 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (12) , 4271-4278
Open AccessStructure Elucidation of the Daptomycin Products Generated upon Heterologous Expression of the Daptomycin Resistance Gene Cluster drcAB
Recently, a high-level daptomycin (DAP)-resistant Mammaliicoccus sciuri strain (TS92) was identified, which mediates a 33% decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here, we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promoter on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine and, subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.
- Open Access
- 7 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Structure elucidation of the daptomycin products generated upon heterologous expression of the daptomycin resistance gene cluster drcAB
Recently, a high-level daptomycin (DAP) resistant Mammaliicoccus sciuri strain (TS92) was identified which mediates a 33 percent decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promotor on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine, and subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.
- 7 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure elucidation of the daptomycin products generated upon heterologous expression of the daptomycin resistance gene cluster drcAB
Recently, a high-level daptomycin (DAP) resistant Mammaliicoccus sciuri strain (TS92) was identified which mediates a 33 percent decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promotor on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine, and subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.
- Open Access
- 30 April 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (8) , e2400032
Identification of active main metabolites of anti‐infective inhibitors of the macrophage infectivity potentiator protein by liquid chromatography using mass detection
Due to increasing antibiotic resistance, the development of anti‐infectives with new mechanisms of action is crucial. Virulence factors such as the “macrophage infectivity potentiator” (Mip) protein, which catalyzes the folding of proline‐containing proteins by means of their cis–trans isomerase (PPIase) activity, have come into focus as a potential new target. Since the inhibition of Mip by small molecules has been shown to lead to reduced virulence and survival in vitro, especially of Gram‐negative bacteria such as Burkholderia pseudomallei (Bp), Neisseria meningitidis (Nm), and Neisseria gonorrhoeae (Ng), or Coxiella burnetii (Cb), among many others, a library of Mip inhibitors was developed. As drug metabolism has a significant impact on the overall therapeutic outcome, this report describes the biotransformation of the most potent Mip inhibitors. Therefore, the anti‐infectives were treated using human liver microsomes in vitro. Liquid chromatography with tandem mass spectrometry (LC/MS‐MS) methods were applied to identify the metabolites and quantify the metabolic degradation of the hit compounds. Active metabolites, N‐oxides, were found, leading to new opportunities for further drug development.
- 30 April 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (8) , e2400032
Open AccessIdentification of active main metabolites of anti‐infective inhibitors of the macrophage infectivity potentiator protein by liquid chromatography using mass detection
Due to increasing antibiotic resistance, the development of anti‐infectives with new mechanisms of action is crucial. Virulence factors such as the “macrophage infectivity potentiator” (Mip) protein, which catalyzes the folding of proline‐containing proteins by means of their cis–trans isomerase (PPIase) activity, have come into focus as a potential new target. Since the inhibition of Mip by small molecules has been shown to lead to reduced virulence and survival in vitro, especially of Gram‐negative bacteria such as Burkholderia pseudomallei (Bp), Neisseria meningitidis (Nm), and Neisseria gonorrhoeae (Ng), or Coxiella burnetii (Cb), among many others, a library of Mip inhibitors was developed. As drug metabolism has a significant impact on the overall therapeutic outcome, this report describes the biotransformation of the most potent Mip inhibitors. Therefore, the anti‐infectives were treated using human liver microsomes in vitro. Liquid chromatography with tandem mass spectrometry (LC/MS‐MS) methods were applied to identify the metabolites and quantify the metabolic degradation of the hit compounds. Active metabolites, N‐oxides, were found, leading to new opportunities for further drug development.
- 18 August 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 235, 115657
The solvent- and surface-dependent adsorption of the lipopeptide antibiotic daptomycin: The general necessity of adsorption tests
- 18 August 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 235, 115657
The solvent- and surface-dependent adsorption of the lipopeptide antibiotic daptomycin: The general necessity of adsorption tests